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The invention of the induced pluripotent stem cell (iPSC) technology allows patient-specific, mature somatic cells to
be converted into an unlimited supply of pluripotent stem cells (PSCs). These iPSCs can then in turn be differentiated
into any cell type including neurons, cardiac cells, pancreatic cells, liver cells, blood cells or enterocytes. Although
cardiovascular disease (CVD) is a leading cause of death in the world, the limited cell derivation and cell number
in cardiac tissue makes it difficult to study the CVDs using the existing cardiac cell model. By differentiating the
patient-specific iPSCs into cardiomyocytes, scientists can generate iPSC-based ‘disease in a dish’ models and use them
to better understand disease mechanism. Here we review the current progress in using iPSC-derived cardiomyocytes
to model human CVDs.
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Recently, human embryonic stem cells (hESCs), used as
pluripotent cells, were widely considered a useful resource
in translational medicine. In 1998, hESCs were isolated
from inner cells of blastocysts and characterized for their
pluripotency and self-renewal [1]. In contrast to adult
stem cells, hESCs can be differentiated into any type of
functional cells. The applications of hESCs in transla-
tional medicine, however, are controversial, and it is
difficult to suppress immunologic rejection in hESC-based
therapies [2].
IPSC: a game changer
Two groups (Yamanaka group in Kyoto University and
Thomson group in University of Wisconsin) separately
reported that somatic cells can be successfully repro-
grammed into iPSCs, marking a major landmark in stem
cell research [3,4]. In each study, four transcription factors
were used for induction. Yamanaka’s group selected Oct3/
4, Sox2, Klf, and c-Myc [3], while. Thomson’s group
used Oct3/4, Sox2, Nanog, and Lin28 [4]. This allowed
researches to reprogram mature somatic cells harvested* Correspondence: jdu@bcm.edu
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reproduction in any medium, provided the orfrom patients and generate an unlimited supply of PSCs
which in turn could be differentiated into various cell
types needed such as neurons, cardiac cells, pancreatic
cells, liver cells, blood cells or enterocytes for disease
modeling, drug screening and cell therapy [5-10]. iPS
cells have a couple of key advantages: they avoid the
ethical concerns that have plagued the embryonic stem
cell field, and they are patient-specific, thus providing a
powerful tool for translational medicine.iPSC for cardiovascular diseases
A straightforward application of iPSCs is to establish
patient-specific genetic disease models in vitro. These
models are useful for understanding mechanism of physi-
ology and pathology of disease, validating therapeutic
targets, and drug screening/discovery. CVD, more com-
monly known as heart disease, encompasses all heart
and blood vessel disease. CVD is the world’s leading
cause of death; more people die annually from CVD
than from any other cause, with an estimated 17.3 mil-
lion people dying in 2008, accounting for 30 % of all
global deaths. CVD encompasses a broad range of disor-
ders such as atherosclerosis, ischemic heart disease, acute
myocardial infraction, valvular heart disease, heart failure,
cardiomyopathies, arrhythmias, hypertension, and con-
genital heart disease. By differentiating patient-specific
iPSCs into patient-specific cardiomyocytes, researchersl Ltd. This is an open access article distributed under the terms of the Creative
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use them to better understand disease mechanism and
develop new therapeutics [11,12]. Ion channels are pore-
forming membrane proteins whose functions allow them
operate like biological micro-machines to establish a
resting potential, shape action potentials, and control
the excitability of neurons, cardiac cells and muscle cells,
thus playing an essential role in functional regulation of
the cardiovascular system. The outward currents (such
as Iks and Ikr encoded by KCNQ1 and human ether-á-go-
go–related gene (hERG) gene, respectively) contribute
to repolarization of cardiac action potentials, which
helps bring membrane potentials back to the resting
level and terminate a ventricular contraction. The tim-
ing of these repolarizing currents (Iks and Ikr) is critical.
Failure to repolarize due to inherited mutations in
KCNQ1 or hERG gene, or drug-induced Iks and Ikr in-
hibitions, for example, can result in abnormalities in
action potentials, thus causing Long QT syndrome
(Type 1 or 2). Moretti et al. [13] were an early example,
taking skin biopsies from patients with Long QT Syn-
drome Type 1 (LQT-1), reprogramming their cells into
iPSCs, and then differentiating those iPSCs into cardiac
cells. These patient-specific cardiomyocytes recapitulated
the clinical presentation of the ‘Long QT’ phenotype [13].
Using a similar approach, [14] successfully modeled Long
QT Syndrome Type 2 (LQT-2). These studies clearly
established iPSC-derived cardiomyocytes as a powerful
tool for drug discovery and personalized medicine [15].
To date, iPSC models have been used to model a large
number of genetic arrhythmias including LQT syndromes,
catecholaminergic polymorphic ventricular tachycardia
(CPVT), arrhythmogenic right ventricular cardiomyopathy
(ARVD), and Overlap Syndrome [14,16-24]. A number of
genetic cardiomyopathies have also been studied using
iPSCs [25]. generated iPSCs from skin cells of patients
in a family with inherited dilated cardiomyopathy (DCM)
carrying a mutation in the TNNT2 gene, a gene encodes
Troponin T type 2 (cardiac) that is the tropomyosin-
binding subunit of the troponin complex and mutations
in this gene have been associated with dilated cardio-
myopathy familial hypertrophic cardiomyopathy as well
as restrictive cardiomyopathy [25]. Compared to cardio-
myocytes derived from iPSCs of healthy controls in the
same family, cardiomyocytes derived from iPSCs of DCM
patients exhibited increased heterogeneous myofilament
organization, susceptibility to stress, compromised ability
to regulate calcium flux, and decreased contractile force.
More recently, Lan et al. reported modeling a familiar
hypertrophic cardiomyopathy (HCM) [26]. Patient-specific
induced pluripotent stem cell cardiomyocytes (iPSC-CMs)
from a ten-member family cohort carrying a hereditary
HCM missense mutation (Arg663His) in the MYH7 gene
were generated. This gene encodes a myosin heavy chainbeta (MHC-β) isoform expressed primarily in the heart.
Diseased iPSC-CMs recapitulated numerous aspects of the
HCM phenotype including cellular enlargement, abnormal
Ca2+ handling and contractile arrhythmia at the single-
cell level. In addition to those early-onset cardiovascular
diseases modeled by iPSC-derived cardiomyocytes men-
tioned above, Kim et al. for the first time demonstrated
late-onset disease models using ARVD/C patient-specific
iPSCs, in which the patients don’t have clinical phenotype
until adulthood [27]. Several groups have reported that
iPS cells can also be differentiated into functional endo-
thelial cells (ECs) or vascular smooth muscle cells (SMCs),
which can shed new light up on understanding the mecha-
nisms of various vascular diseases such as hypertension,
pulmonary atrial hypertension (PAH), coronary heart dis-
ease, and diabetic cardiomyopathy. There are, however,
fewer vascular diseases being modeled by iPSCs thank
cardiac diseases [28-32]. Kinnear et al. generated iPSCs
from a patient with aortic and pulmonary stenosis who
was suffering from Williams-Beuren syndrome (WBS), a
rare genetic neurodevelopmental disorder that can cause
cardiovascular disease [33]. Interestingly, WBS patient-
specific iPS cell-derived SMCs demonstrate an immature
proliferative phenotype with reduced functional and con-
tractile properties compared to healthy controls, thereby
recapitulating the human disease phenotype. Moreover,
they showed that the long-term treatment (5 days) of the
antiproliferative drug rapamycin can rescue the disease
phenotype, providing an attractive therapeutic candidate
for patients with WBS and vascular stenosis.
Review and conclusions
A growing number of research groups have employed
iPSCs to model CVDs. It remains unclear whether diseased
iPSC-derived cardiomyocytes show disease phenotypes
in vitro and how similar in vitro phenotypes are to their
clinical equivalents. It is to be noted that iPSC-derived
cardiomyocytes are morphologically and electrophysiolog-
ically immature compared to human adult counterparts.
Several studies have focused on developing methologies to
obtain more mature cardiomyocytes derived from iPSCs
[34]. iPSC-derived cardiomyocytes are also a mixture of 3
subtypes of cells (ventricular-like, atrial-like, nodal-like).
All three differentiation methods including embryoid body
formation, endodermal induction and directed differen-
tiation method reflect these shortcomings. Future chal-
lenges will focus on how diseased iPSC models can
faithfully reflect disease phenotypes. Published iPSC stud-
ies only reproduce disease phenotypes and drugs that have
already been reported using other approaches such as
transgenetic animal models or primary cells. Moreover,
most of the published iPSC disease model works are
the ones looking into arrhythmic disorders carried ion
channel gene mutations. To demonstrate the power of
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discover novel drug targets, and investigate more compli-
cated cardiovascular diseases. In conclusion, although
iPSC-based cardiovascular disease research is in its in-
fancy, further improvement and standardization of the
culturing methods can lead to a more comprehensive
understanding of mechanisms in cardiovascular disease.
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